SCHEMBL502201

SCHEMBL502201

N#CCc1cc(Cl)cc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
TSHR P16473 1/20 0.42
IDO1 P14902 2/20 0.41
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
ENPP2 Q13822 1/20 0.36
CYP2A6 P11509 1/20 0.36
MMP3 P08254 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
KMT2A Q03164 1/20 0.32
ATM Q13315 1/20 0.32
S100A9 P06702 2/20 0.31
HTR3E A5X5Y0 1/20 0.31
HTR3B O95264 1/20 0.31
HTR3A P46098 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8658364 0.95 KDM4E (0.48) KDM4ETDP1TSHRIDO1NPC1
SCHEMBL4433177 0.89 KDM4E (0.41) KDM4ETDP1TSHRIDO1NPC1
SCHEMBL585527 0.84 KDM4E (0.41) KDM4ETDP1TSHRIDO1NPC1
SCHEMBL1072135 0.84 KDM4E (0.41) KDM4ETDP1IDO1NPC1LMNA
SCHEMBL501685 0.84 KDM4E (0.41) KDM4ETDP1NPC1LMNAMAPT
SCHEMBL334575 0.84 KDM4E (0.41) KDM4ETDP1IDO1NPC1LMNA
SCHEMBL28140280 0.84 KDM4E (0.38) KDM4ETDP1IDO1NPC1LMNA
Bromide SCHEMBL4765026 0.81 KDM4E (0.39) KDM4ETDP1TSHRIDO1NPC1
SCHEMBL4007007 0.80 KDM4E (0.52) KDM4ETDP1NPC1LMNAMAPT
SCHEMBL25369080 0.80 KDM4E (0.38) KDM4ETDP1NPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106748988-B A kind of method that supercritical ultrasonics technology synthesizes the halogenated -3- substituted hydrocarbon radical sulfonyl pyridine of 2- and its intermediate 山东师范大学 2019-05-28 CN claimed
CN-109613155-A A kind of detection method of armaticity nitrogenous disinfection byproducts 同济大学 2019-04-12 CN claimed
CN-106518757-A Method for synthesizing 2-halo-3-substited alkylsulfonyl pyridine and intermediate compound thereof through microwave method 山东师范大学 2017-03-22 CN claimed
WO-2025104443-A1 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-05-22 WO disclosed
CN-111253404-B Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof 上海医药集团股份有限公司 2023-05-23 CN disclosed
CN-110573512-B Heterocyclic compounds 武田药品工业株式会社 2022-09-06 CN disclosed
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2022-02-17 US disclosed
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2022-01-20 US disclosed
EP-3889156-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2021-10-06 EP disclosed
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors BIAL—PORTELA & CA, S.A. (PT) 2021-04-13 US disclosed
US-10919891-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-02-16 US disclosed
EP-0638070-A1 FUNGICIDAL ARYLPYRAZOLES RHONE-POULENC AGROCHIMIE (FR) 1995-02-15 EP disclosed
CN-1079735-A Arylpyrazole mycocide ENERGY BIOSYSTEMS CORP (FR) 1993-12-22 CN disclosed
WO-1993022287-A1 FUNGICIDAL ARYLPYRAZOLES RHONE POULENC AGROCHIMIE (FR) 1993-11-11 WO disclosed
US-5136080-A Intermediates for glutamate inhibitors BURROUGHS WELLCOME CO. (US) 1992-08-04 US disclosed
EP-0459819-A2 Pharmacologically active CNS compound THE WELLCOME FOUNDATION LIMITED (GB) 1991-12-04 EP disclosed
CN-1052306-A Compounds having pharmacological activity on the central nervous system WELLCOME FOUND (GB) 1991-06-19 CN disclosed
EP-0372934-A2 Pharmacologically active CNS compounds THE WELLCOME FOUNDATION LIMITED (GB) 1990-06-13 EP disclosed
US-4447454-A Analgetic compounds, compositions and process of treatment THE UPJOHN COMPANY (US) 1984-05-08 US disclosed
US-4113866-A ANALGETIC COMPOUNDS, COMPOSITIONS AND PROCESS OF TREATMENT THE UPJOHN COMPANY (US) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS DBH, SLC6A3, SLC6A2 KDM4E 3207/4885TDP1 762/4885TSHR 985/4885
US-10919891-B2 Heterocyclic compound CASR, AGTR2, AGTR1 KDM4E 3607/4885TDP1 4808/4885TSHR 612/4885
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors DBH, SLC6A3, SLC6A2 KDM4E 3244/4885TDP1 861/4885TSHR 937/4885
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof MAPK11, WEE1, NOS1 KDM4E 3284/4885TDP1 3093/4885TSHR 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.